Type
|
Size
(nm)
|
Synthesis technique
|
Mode of administration
|
Mechanism for delivery
|
Drug release mechanism
|
Example
|
Drug
|
disease
|
Patent
|
PNP |
10-1000 |
|
Subcutaneous, intravenous and oral |
|
|
Chitosan-coated erythropoietin (HMG-Co-A reductase inhibitors) |
Brain targeting |
US20070237827 |
PLGA encapsulated NMDA-NR1 vaccine |
Alzheimer’s disease |
US20100173004 |
SLN |
50-1000 |
|
Nasal, oral, parenteral, rectal and respiratory |
|
|
LDL-cholesterol conjugates |
AD, PD, and cancer |
US7682627 |
LDL nanoparticles |
Epilepsy, stroke, Trauma and AD |
US20060222716 |
Micelles |
80-100 |
|
Pulmonary delivery |
Receptor-mediated transport, absorption, and endocytosis |
Bursting, diffusion, and cleavage |
doxorubicin, vincristine sulphate loaded poly (L-histidine)-poly(ethylene glycol) block copolymer and PLEG poly micelles |
Cancer |
US7659314 |
Paclitaxel-loaded copolymer micelle |
Lung cancer |
NCT01023347 |
Nanoliposomes |
Less than 100 |
|
Pulmonary delivery, intravenous, |
Adsorption, fusion and diffusion/ endocytosis |
Endocytosis and Adsorption to cell surface Bursting due to environmental stimuli |
Glutathione encapsulated liposomes |
Myoclonus |
US20100166846 |
Tempamine loaded liposome |
Multiple sclerosis and PD |
US20110027351 |
CNTs |
Diameter of 3.5-70nm |
|
mainly intraperitoneal and intravenous |
Endocytosis, diffusion, penetration |
Electrically or chemical controlled |
Streptavidin-HRP (Horseradish peroxidase) bounded SWCNT-annexin conjugates |
Breast cancer |
US201001846691A1 |
Stem cell loaded CNT |
AD, PD, and ischemia |
US20090148417A1 |
Dendrimers |
Diameter range 1.5-13.5 |
Divergent method- Micheal reaction
Convergent method
Click chemistry- Diels_alder reactions, azide-alkyne reaction, and thiol-yne reactions
Hypercore & branched monomers
|
Oral, transdermal, topical, IV |
Transcytosis and endocytosis |
Degradation and environmental stimuli |
Anxiolytic and antipsychotic agents |
Psychotic disorder |
US20100160299 |